Plain-English translation of NCT06592170 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lymphoma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new combination of two medications—linperlisib and obinutuzumab—as a first-line treatment for marginal zone lymphoma, a type of lymphoma (blood cancer). The study aims to find the safest dose of the medication and to see how well this combination works at shrinking tumors and controlling the disease. Researchers will monitor both how effective the treatment is and what side effects patients experience.
Marginal zone lymphoma is a slow-growing cancer that needs better treatment options. This trial exists to see whether this new medication combination could offer patients improved outcomes compared to existing treatments.
You likely qualify if…
You likely don't qualify if…
The trial has two phases. In the first phase, a small group of patients will receive the medication combination to determine the safest dose. In the second phase, more patients will receive two cycles of both medications given together, followed by maintenance therapy with the medication alone for up to 24 months. You will take the medication by mouth daily and receive intravenous infusions on specific days. Throughout the trial, you will have regular blood tests, scans, and appointments to monitor how well the treatment is working and track any side effects.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China